semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Infiltrating Ductal Carcinoma Invasive non-lobular breast cancer, histologically proven by biopsy Tumour T2 T3 regardless of nodal status, stemming from a primary surgery, in whom FDG-PET is performed for staging Age greater than or equal to 18 years Good condition: WHO lower 2 Women receiving effective contraception throughout the duration of treatment and 3 months after cessation of treatment Patient has signed informed consent  Carcinoma other than breast ductal carcinoma Patients for whom no target tumor is assessable Patients for whom surgery first of their breast cancer is not indicated (tumor spread, metastasis, general health, co-morbidities) Pregnant women, or likely to be during breastfeeding Major protected (under supervision and under guardianship) Failure to submit to medical supervision of the study for reasons of geography, social or psychological Incomplete tumor resection
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Infiltrating Duct and Lobular Carcinoma In Situ Invasive Lobular Breast Carcinoma Inflammatory Breast Carcinoma Previously untreated (no chemotherapy, hormonal or radiation therapy)invasive breast cancer Diagnosis of invasive ductal or lobular breast cancer plus or minus DCIS. Inflammatory carcinoma will also be elegible Age≥ 18 years Only female patients are eligible Tumor≥ 1.0cm by MRI and/or sonographic or clinical exam measurements. If the tumor is <1.0 but the patient has biopsy proven lymph node metastasis, she will also be considered eligible.Although only tumors≥2cm are consideredmeasurable by we will nevertheless tumors≥1cm since the primary endpoint is pathological CR rate Performance status ECOG≤2 or Karnofsky≥ 50% Peripheral neuropathy≤ grade 1 Hematologic (minimal values):Absolute Neutrophil count≥1,500/mm³; Hemoglobin≥8.0g/dl; Paltelet count≥100,000/mm³ Hepatic; Total bilirubin≤ULN AST and ALT and ALP do not have to be within the range. In determining the more abnormal of the two values(AST or ALT) should be use as per protocol table on p.24of 69 Women of childbearing potential must have a negative pregnancy test  Pregnant or breast feeding patients are excluded Patients with second malignancies with expected survival<5 years Previous chemotherapy with Taxanes,Anthracyclines or Cyclophosphamide Patientes with history of severe hypersensitivity reaction to Taxotere(Docetaxel)or other drugs formulated with polysorbate 80 Pure DCIS diagnoses are not elegible Special histologies with favorable prognosis such as mucinous, tubular are not elegible Patients with reduced ejection fraction<50% are not eligible Patients with tumors<1.0cm unless biopsy proven axillary node metastasis present Cardiac thrombotic events in the past 12 months Stroke or transient ischemic attacks (TIA) within 12 months
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-65.0,  Fasting Malignant Neoplasm of Stomach Patients who are diagnosed with gastric adenocarcinoma years old and blew Patients are expected to be undergone distal subtotal gastrectomy No complication by gastric cancer No synchronous metastatic lesions Laparoscopic or robotic surgery Informed consent  Previous gastrectomy history Combined surgery due to synchronous malignancy Patients with major organ dysfunction
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 50.0-999.0,  Breast Cancer The patient must consent to be in the study and must have a signed an approved consent form conforming with institutional guidelines Patient must be > 50 years old The patient should have a life expectancy of at least two years with a karnofsky performance status > 70 The patient must have stage 0 or I breast cancer On histological examination, the tumor must be DCIS or invasive adenocarcinoma of the breast Surgical treatment of the breast must have been lumpectomy. The margins of the resected specimen must be histologically free of tumor (>2mm, DCIS and invasive). Re-excision of surgical margins is permitted Gross disease must be unifocal with pathologic (invasive and/or DCIS) tumor size 2 cm or less. (Patients with microscopic multifocality are eligible as long as total pathologic tumor size is 2 cm or less.) Patients with invasive breast cancer are required to have axillary staging which can sentinel node biopsy alone (if negative), sentinel node biopsy followed by axillary dissection or sampling with a minimum total of 6 axillary nodes or axillary dissection alone (with a minimum of 6 axillary nodes). Axillary staging is NOT required for patients with DCIS The patient must have simulation within 8 weeks/56 days of the final surgery for their breast cancer (lumpectomy, re-excision of margins, or axillary staging procedure) Patients with a history of non-ipsilateral breast malignancies are eligible if they have been disease-free for 2 or more years prior to enrollment. Patients with the following cancers are eligible even if diagnosed and treated within the past 2 years: carcinoma in situ of the cervix, colon, melanoma in situ, and basal cell and squamous cell carcinoma of the skin  Men are not eligible for this study as men are not breast conservation candidates T0, T2 (> 2.0 cm), T3, node positive, stage III or IV breast cancer Any positive axillary nodes Palpable or radiographically suspicious ipsilateral or contralateral axillary, supraclavicular, infraclavicular or internal mammary nodes, unless biopsy proven to be negative for tumor Suspicious microcalcifications, densities or palpable abnormalities in either breast unless biopsy proven to be benign Non-epithelial breast malignancies such as sarcoma or lymphoma Proven multicentric carcinoma in more than one quadrant or separated by more than 2 centimeters Paget's disease of the nipple History of invasive breast cancer or DCIS in the same breast Surgical margins that cannot be microscopically assessed or are less then 2 mm
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Breast Cancer Karnofsky ≥ 70 2. Provision of informed consent 3. Pathological confirmation of invasive ductal carcinoma and estrogen receptor is positive 4. Tumor stage(TNM):T2-4bN0-3M0 5. Premenopausal woman 6. Not previously received treatment with bisphosphonate 7. Laboratory PLT ≥ 100*109/L WBC ≥ 4000/mm3 HGB ≥ 10g/dl GOT,GPT,ALP ≤ 2*ULN TBIL,DBIL,CCr ≤ 1.5*ULN  Pregnant or lactation woman 2. History of organ transplantation 3. With mental disease 4. With severe infection or active gastrointestinal ulcers 5. With severe liver disease (such as cirrhosis), kidney disease, respiratory disease or diabetes 6. Disease-free period of other malignant tumor is less than 5 years(except cured basal cell skin cancer and cervical carcinoma in situ) 7. With heart disease 8. Experimental drug allergy
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Metastatic Brain Tumors Progression Radiation Necrosis Quality of Life Key 1. Patient has signed and received a copy of the Informed Consent Form 2. Patient may have up to 3 target supratentorial metastatic lesions previously treated with stereotactic radiosurgery, with radiological evidence of progression, pseudoprogression or radionecrosis. Subject may have additional non target lesions present as long as they are not expected (in Investigator's judgment) to contribute to symptomatology during the course of the study or confound interpretation of radiological and clinical measures. 3. Karnofsky Performance Status (KPS) ≥ 60. Key  Females who are pregnant, breast feeding, or plan to become pregnant in the 6 months following index procedure. 2. Leptomeningeal metastases. 3. Uncontrolled infectious process. 4. Uncontrolled hypertension (systolic >180 mm Hg), angina pectoris, or cardiac dysrhythmia, or recent (within 6 weeks) history of intracranial hemorrhage. 5. Serious infection, immunosuppression or concurrent medical condition (chronic or acute in nature) that may prevent safe participation or ability to meet follow-up requirements. 6. Abnormal absolute neutrophil count (ANC<1000/mm), platelets (<100,000/mm) or the administration of antiplatelet agents (aspirin, plavix etc) or anticoagulation within 7 days prior to treatment. 7. Inadequate bone marrow, liver and renal function (e.g., total bilirubin > 1.5 x ULN; AST, ALT > 2.5 x ULN; alkaline phosphatase > 2.5 x ULN; serum creatinine > 1.5 x ULN)
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Vertebral Metastasis Histological confirmation of malignancy (non-small cell lung cancer, breast cancer (hormone refractory), prostate cancer (hormone refractory), lymphoma, renal cell carcinoma, myeloma by either biopsy or cytology of the primary or metastatic lesion Patients must have radiological documentation of metastatic disease to the thoracic or lumbar spine including both positron emitted tomography (PET) or nuclear medicine bone scan (NMBS) and Magnetic Resonance Imaging (MRI) within 4 weeks prior to study entry Patients with one to three spinal metastases to the thoracic or lumbar spine will be included Spinal metastatic lesions should be limited to one vertebral body level or ≤ 6cm in greatest dimension Tumors should not directly abut the spinal cord, and have at least 5mm separation from the spinal cord. For patients with tumors closer than 5mm, is permissible at the discretion of the treating radiation oncologist such that dosimetric review demonstrates that the total dose to spinal cord is within tolerable range of <10Gy to 10% partial volume or max point dose 18 Gy Patients must be able to fit into either the Elekta Stereotactic Body Frame or the Elekta Stereotactic BodyFix immobilization device Must be ≥ 18 years of age ECOG status 0-2 Women of childbearing potential and male participants must use an effective contraception method. (Until at least 60 days following treatment.) Negative urine pregnancy test within at least one week before starting treatment in women of child-bearing age  Patients with evidence of spinal instability OR neurologic deficit resulting from bony compression of neurologic structures Patients with other systemic illness, or have not recovered adequately from their primary treatment or who have evidence of progression of their current cancer prior to therapy that, in the investigator's opinion, would preclude their inclusion Patient may not receive concomitant cytotoxic anti-neoplastic therapy during treatment. Patients may be allowed to use hormonal suppression therapy or bisphosphonates for hypercalcemia Pregnant or lactating women Any patient with symptoms of pain, compression fracture, neurologic deficit will not be included Patients previously treated with radiation therapy to the thoracic or lumbar spinal levels of involved disease will not be included
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 20.0-70.0,  Locally Advanced Breast Cancer Patients with histologically proven invasive breast cancer the primary tumor size is at least 5cm or cytologically proven axillary node metastasis 2. no evidence of systemic metastasis pathologically or radiologically 3. age at the time of diagnosis between 20 and 70 years 4. patients with previously untreated primary breast cancer including chemotherapy 5. general performance status with ECOG 0-2 6. sufficient hematopoietic function (absolute neutrophil count of ≥ 1,500/mm3, platelet count of ≥ 100,000/mm3, and hemoglobin of ≥ 10 g/dL) 7. sufficient renal function (serum creatinine level of ≤ 1.5 mg/dL) 8. sufficient liver function (total serum bilirubin level ≤ 1.5 times the upper normal limit; serum AST and ALT levels ≤ 1.5 times the upper normal limit; and serum alkaline phosphatase level ≤ 1.5 times the upper normal limit) 9. sufficient cardiac function (normal electrocardiography within 1 month or LVEF>50% by echocardiography or MUGA scan within 3 months) 10. patients who agree to enroll this clinical trial and sign the written informed consent voluntarily  patients with evidence of distant metastases 2. patients with other previous malignancy except breast cancer 3. pregnant (positive hCG test 1 week before registration) or lactating patient 4. uncontrolled serious infection 5. patients with psychiatric disease or epilepsy 6. patients with clinically severe cardiac disease within 6 months such as atrial or ventricular arrhythmia, congestive heart failure, myocardial infarction, or unstable angina 7. male breast cancer 8. patients with poor general condition who are not able to understand or sign the written informed consent
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Female Breast Cancer histologically confirmed invasive carcinoma of the female breast, status post definitive surgery (lumpectomy or mastectomy plus nodal evaluation if feasible). Patients must initiate therapy with ddTC within 84 days of the last breast or axillary surgery performed for curative intent candidate for chemotherapy by the treating oncologist Patients with pN2 or pN3 disease are NOT explicitly excluded. However, patients with N2 or N3 disease MUST be reviewed with the PI or study chair before being enrolled on the study as TC would not normally be considered adequate therapy for such patients Patients with bilateral, synchronous invasive breast cancer are eligible as long as both primary tumors meet the criteria Patients with estrogen-receptor (ER) and/or progesterone receptor (PR) negative, positive, or unknown tumors are eligible Patients with HER2 positive, negative or unknown disease are eligible for this trial. Patients whose tumors are HER2 positive by either immunohistochemistry (IHC) 3+ staining or demonstrate gene amplification by FISH should receive trastuzumab, following completion of adjuvant cytotoxic therapy with 4 cycles of ddTC There must be negative surgical margins for invasive cancer and DCIS. LCIS is acceptable at the margin Patients with multi-centric breast cancer are eligible as long as all known disease is resected from the breast with negative margins Age >18 years ECOG performance status ≤ 1  Patient has received previous trastuzumab, chemotherapy, hormonal therapy, or other anti-cancer agents (including investigational agents) for this malignancy Patient will be receiving GNRH agonists such as goserelin (Zoladex) or leuprolide acetate (Lupron) concomitantly with chemotherapy for the purpose of preventing breast cancer recurrence Patient has inflammatory breast cancer (pT4d) or metastatic breast cancer Patient has uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia or psychiatric illness/social situations that would limit compliance with study requirements Patient has pre-existing persistent neuropathy The patient has received prior chemotherapy or radiotherapy or any malignancy within the past 2 years Patient has received prior docetaxel or cyclophosphamide within the past 5 years Patient has known contraindication or hypersensitivity to docetaxel, cyclophosphamide or pegfilgrastim
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Patients must have a histologically confirmed diagnosis of invasive breast carcinoma with positive estrogen (ER) and/or progesterone-receptor (PR) status, and negative human epidermal growth factor receptor (HER)2, for whom standard adjuvant endocrine therapy is planned ER and PR positivity must be assessed according to American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines as either ER or PR ≥ 1% positive nuclear staining HER2 test result negativity must be assessed as per ASCO/CAP 2013 guidelines using IHC, ISH or both. HER2 is negative if a single test (or all tests) performed in a tumor specimen show: 1. IHC negative (0 or 1+) 2. ISH negative using single probe or dual probe. If IHC is 2+, evaluation for gene amplification (ISH) must be performed and the ISH must be negative; ISH is not required if IHC is 0 or 1+. HER2 equivocal is not eligible Patients must not have metastatic breast cancer (stage IV disease); patients with multifocal, multicentric, and synchronous bilateral, and primary inflammatory breast cancers are allowed Multifocal disease is defined as more than one invasive cancer < 2 cm from the largest lesion within the same breast quadrant Multicentric disease is defined as more than one invasive cancer ≥ 2 cm from the largest lesion within the same breast quadrant or more than one lesion in different quadrants Synchronous bilateral disease is defined as invasive breast cancer with positive lymph nodes (axillary or intramammary) in at least one breast, diagnosed within 30 days of each other Patients must be high risk by belonging to one of the following risk groups Completion of adjuvant chemotherapy and pathologically negative axillary nodes, and a tumor measuring ≥ 2 cm in greatest diameter, and an Oncotype DX® recurrence score (RS) > 25 (completed as standard of care). Patients with micrometastases as the only nodal involvement (pN1mi) are eligible, and will be categorized as node-negative